TECKRO
9.11.2021 15:06:09 CET | Business Wire | Press release
Teckro, creator of the only clinical trial platform that facilitates collaboration between and among stakeholders, today announced the launch of the Totally Clinical: Trial Triumphs & Rad Trends podcast. The series provides a medium for diverse stakeholders in the clinical trial ecosystem to engage in conversation; inspiring new ways to design, deliver, and improve participation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005899/en/
To promote the new podcast series, Teckro worked with award-winning actor John C. McGinley. Known as Dr. Perry Cox in the hit television series Scrubs , McGinley stars in a video introducing Totally Clinical .
Totally Clinical episodes cover a variety of topics, ranging from field research perspectives and patient experiences, to drug development advances and technology trends. Gary Hughes, Teckro co-founder and CEO, kicks off the series by talking about operating for the greater good and what it means to be a mission-driven company in the 21st Century.
“Teckro is already the hub for effective communication; connecting stakeholders despite the complex, distributed, and often siloed nature of clinical trials,” says Hughes. “Now with the introduction of the Totally Clinical podcast, we are broadening our ambition to engage even more stakeholders in conversations; advancing clinical research and expanding awareness of clinical trials as an option for best possible care.”
Other topics include:
- Dr. Deborah Zajchowski, scientific director for the non-profit Clearity Foundation , discusses how targeted clinical trials based on tumor biomarkers can help increase survival rates for ovarian cancer.
- Dr. Brendan Buckley, Teckro Chief Medical Officer, explores trends in clinical trials –from mega trials to personalized medicine.
- Lydia Beaudette, manager of growth at LMC Manna Research , presents the research site viewpoint and ways to reduce the burden of technology on staff who are already stretched thin.
- Maria Milas takes us through the “day in the life” of a clinical research associate (CRA) and how the pandemic is driving change for the better.
- And Martin Lovell, a prostate cancer survivor, recounts how a chance reading of a newspaper article saved his life.
“Every initiative that gets people talking is a step forward,” says Dr. Zajchowski, “but the Totally Clinical podcast series is also a chance for non-profit organizations to reach other audiences. It allows us to engage in conversations that might accelerate research for treatments and drugs that improve outcomes and survival.”
The Totally Clinical: Trial Triumphs & Rad Trends podcast is available ad-free on Spotify , Apple , and Google . If you are interested in submitting a topic for consideration, contact us .
About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials. Teckro works with emerging biotech and global pharmaceutical organizations, including 12 out of the Top 20 companies. Teckro supports all therapeutic areas, all phases, and any trial format including traditional in-clinic, decentralized clinical trials, or a hybrid approach.
More Information
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005899/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones29.10.2026 07:36:00 CET | Press release
ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV)Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) reviewLate-stage pipeline continues to advanceFY2026 full-year outlook upgraded to reflect foreign exchange (FX) benefitTakeda will host a Capital Markets Day on Dec. 11, 2026, in Tokyo, Japan Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda’s focus remains on execution against the first horizon of its growth strategy: successfully launching three new medicines, advancing its late-stage pipeline
AB InBev Reports Third Quarter 2026 Results29.10.2026 07:01:00 CET | Press release
Solid top- and bottom-line performance with volume growth, revenue up 4.9% and Underlying EPS up 22% Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028546637/en/ Regulated and inside information1 “Delivering solid growth today while investing for tomorrow - our portfolio of megabrands and mega platforms continues to win with consumers, and our performance this quarter reflects the strength of our diversified footprint, best-in-class capabilities and consistent execution of our strategy. Thank you to our colleagues around the world for their commitment and dedication as we continue to compound growth and create long-term value.” – Michel Doukeris, CEO, AB InBev Revenue +4.9% Revenue increased by 4.9% in 3Q26 with revenue per hl growth of 4.2% and by 5.4% in 9M26 with revenue per hl growth of 4.3%. Reported revenue increased by 9.1% in 3Q26 to 16 512 million
EIG and Acwa Announce Plenum Power, a Strategic Partnership to Invest in U.S. Power Infrastructure29.10.2026 06:00:00 CET | Press release
Partnership combines EIG’s platform-building, investment and financing expertise with Acwa’s large-scale power development and operating capabilities and is targeting a launch with approximately $4 billion of initial equity commitment EIG, a leading institutional investor in the global energy and infrastructure sectors, and Saudi-listed Acwa, one of the world's largest independent power producers, today announced that they have entered into definitive agreements to establish Plenum Power, a strategic partnership focused on investment opportunities in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028377569/en/ Dr. Samir J. Serhan, Chief Executive Officer of Acwa (left), and R. Blair Thomas, Chief Executive Officer of EIG (right) Building on an established relationship that includes prior collaboration on projects in the Middle East, EIG and Acwa are now partnering to pursue opportunities in the U.S. pow
Murata Launches World’s Smallest RF / Microwave Coaxial Connectors with a Switch, Cutting PCB Mounting Area by Approximately 40%29.10.2026 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of the SWL series MM8330-2600RJ5 and MM8330-2600RK20, the world’s smallest RF / microwave coaxial connectors with a switch*. Measuring just 1.0 mm × 1.0 mm × 0.55 mm, the new connectors reduce PCB mounting area by approximately 40% compared with Murata’s previous SWJ series. When used with dedicated probes, the SWL series reduces its PCB footprint, including the keep-out area, by approximately 60% compared with Murata’s previous SWJ series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028261665/en/ [Murata Manufacturing Co., Ltd.] RF / microwave coaxial connectors with a switch As wireless devices incorporate more functionality, rising component counts are placing increasing pressure on limited PCB space. RF test connectors require not only mounting area for the connector itself, but also sufficient clearance around the component
FuriosaAI Secures $620 Million Series D to Meet Surging Enterprise AI Inference Demand and Accelerate Next-Gen Silicon29.10.2026 00:57:00 CET | Press release
Global investors, including Infinitum, Jericho Capital, QUDA Capital, Cisco Investments, and Worldline Capital, join the round alongside the National Growth Fund of Korea and Korean institutions. FuriosaAI, an AI semiconductor company building sustainable, high-performance inference compute for data centers, today announced the completion of its $620 million (KRW 820 billion) Series D round, bringing its post-money valuation to approximately $2.9 billion. The financing marks a major milestone as FuriosaAI scales global commercial deployments of its RNGD AI inference accelerator. FuriosaAI will use the new capital to expand RNGD production, strengthen its software ecosystem, and accelerate development of its third-generation AI accelerator. International investors contributed a total of $110 million to the round, bringing deep expertise across AI semiconductors and computing infrastructure. U.S.-based Infinitum, an investment firm with extensive experience in the AI semiconductor sector
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom